INMED PHARMACEUTICALS INC

ADAR1 Capital quietly adds 1,000 InMed Pharma shares at $1.56, signaling confidence in its cannabinoid pipeline and a patient, data‑driven strategy that could boost long‑term value.

ADAR1 Capital’s May 2026 buy‑spree of 468,551 InMed shares shows bullish confidence in its merger with Mentari and a potential surge in migraine‑therapy value.

ADAR1 Capital’s new 331,449‑share stake in InMed Pharmaceuticals signals rising confidence amid a Mentari merger, offering a potential low‑price entry for biotech investors.